A new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
23/02/2021 – AB Science announces that a new independent publication confirms the role of masitinib as a potential therapy in pancreatic cancer
A new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro
25/01/2021 – AB Science announces that a new independent publication confirms that masitinib has anti-viral activity against the SARS-CoV-2 virus in vitro and is a promising candidate for treating Covid-19
Capital raise for a total amount of 15 million euros
21/12/2020 – AB Science announces today the success of its capital raise for a total amount of 15 million euros
Results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
18/12/2020 – AB Science communicates the results from phase 2B/3 study evaluating masitinib in Alzheimer’s disease
Masitinib in Alzheimer’s Disease Webcast Presentation
17/12/2020 – Presentation of the webcast held on December 17, 2020 on masitinib in Alzheimer’s Disease
Results of the Extraordinary General Shareholders’ Meeting of December 16, 2020
17/12/2020 – AB Science provides the results of the Extraordinary Shareholders’ Meeting of December 16, 2020
Corrective press release regarding adverse events information from study AB09004
17/12/2020 – AB Science issues a corrective press release regarding adverse events information from study AB09004 reported on December 16, 2020
Live webcast on Thursday December 17, 2020 on masitinib’s results in Alzheimer’s Disease
16/12/2020 – AB Science will host a live webcast on December 17, 2020 on masitinib results in Alzheimer’s Disease
Positive Phase 2/3 study AB09004 with masitinib in Alzheimer’s Disease
16/12/2020 – AB Science announces that Phase 2B/3 study evaluating masitinib in Alzheimer’s disease met its primary endpoint
Live webcast on Friday December 11, 2020 on masitinib’s results in pancreatic cancer
08/12/2020 – AB Science will host a live webcast on December 11, 2020 with key opinion leaders to discuss recently reported results from the Phase 3 masitinib trial in pancreatic cancer